<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117402</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 588</org_study_id>
    <nct_id>NCT01117402</nct_id>
  </id_info>
  <brief_title>Tomotherapy in Postsurgery Recurrent Carcinoma Cervix</brief_title>
  <official_title>Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy is the most appropriate treatment for postoperative recurrent carcinoma cervix.&#xD;
      However it is technically difficult to deliver adequate doses of RT due to presence of small&#xD;
      intestines in the radiation area; thus disease control rates are poor and complication rates&#xD;
      are high with conventional radiotherapy. Use of IMRT and brachytherapy for these cases allows&#xD;
      for increasing dose to the tumor while sparing normal structures. It is expected that the use&#xD;
      of a combination of IMRT &amp; brachytherapy will achieve higher disease control rates and&#xD;
      decrease the complication rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SPECIFIC OBJECTIVES:&#xD;
&#xD;
        1. To evaluate the efficacy of combination of intensity-modulated radiotherapy (IMRT) and&#xD;
           brachytherapy in delivering dose escalated radiotherapy in postoperative residual /&#xD;
           recurrent cases of carcinoma cervix, in terms of local control proportion and&#xD;
           progression free survival (PFS)&#xD;
&#xD;
        2. To study the late and acute toxicities associated with this treatment.&#xD;
&#xD;
        3. Dosimetric comparison of Tomotherapy and conventional IMRT&#xD;
&#xD;
      DESIGN: Prospective, phase II study.&#xD;
&#xD;
      STUDY POPULATION: All patients of age &lt; 65 years diagnosed with postsurgery recurrent&#xD;
      squamous cell carcinoma cervix without previous history of radiotherapy.&#xD;
&#xD;
      STUDY SIZE: 90 patients&#xD;
&#xD;
      METHODOLOGY: Ninety cases of cervical cancer with postsurgery recurrence limited to the&#xD;
      pelvis will be screened and taken for study if eligible after taking the informed consent.&#xD;
&#xD;
      Patients will receive external radiation therapy using IMRT to pelvis with additional dose of&#xD;
      localized radiotherapy boost with brachytherapy to the vault with weekly concurrent&#xD;
      chemotherapy.&#xD;
&#xD;
      The local recurrence rate and 5 year disease free survival rate of all the patients will be&#xD;
      studied.&#xD;
&#xD;
      PROJECT PERIOD:&#xD;
&#xD;
      Total project period : 5 years Recruitment, Data collection : 4 years Complete analysis of&#xD;
      data : 1 year&#xD;
&#xD;
      STUDY SITE: Tata memorial centre&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the utility of intensity-modulated radiotherapy (IMRT) in delivering dose escalated radiotherapy in postoperative recurrent cases of carcinoma cervix, in terms of local control</measure>
    <time_frame>3 Years</time_frame>
    <description>Progression free survival of all patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the late toxicities associated with this treatment</measure>
    <time_frame>3 Years</time_frame>
    <description>Side effects of radiotherapy and chemotherapy will be recorded at baseline, during treatment, at 6 and 12 months and annually thereafter according to the RTOG scales</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postsurgery Recurrent Carcinoma Cervix</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.&#xD;
Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions.</description>
    <other_name>IMRT</other_name>
    <other_name>Template brachytherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        . Only histologically proven postoperative recurrence of squamous carcinoma of cervix&#xD;
        following hysterectomy &gt;3 months without adjuvant treatment&#xD;
&#xD;
          -  Patients below 65 years of age and with KPS &gt;70%.&#xD;
&#xD;
          -  Patients with disease confined to the pelvis, based on CT/MRI/PET Scan&#xD;
&#xD;
          -  Normal ECG and cardiovascular system&#xD;
&#xD;
          -  Normal hematological parameters&#xD;
&#xD;
          -  Normal renal and liver function tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy or radiotherapy to the pelvis&#xD;
&#xD;
          -  Pelvic LN &gt;3cm in size&#xD;
&#xD;
          -  Presence of disease outside the pelvis (Paraortic nodes, distant metastasis)&#xD;
&#xD;
          -  Bilateral hydronephrosis&#xD;
&#xD;
          -  Co-morbid conditions like uncontrolled Diabetes Mellitus or medical renal disease&#xD;
&#xD;
          -  Medical or Psychological condition that would preclude treatment&#xD;
&#xD;
          -  Patient unreliable for treatment and follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reena Engineer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tata Memorial Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reena Engineer, MD</last_name>
    <phone>+912224177165</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ShyamKishore Shrivastava, MD</last_name>
    <phone>+912224177163</phone>
    <email>shrivastavask@tmc.gov.in</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tata Memorial Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Engineer, MD</last_name>
      <phone>+912224177165</phone>
      <email>reena_engineer@rediffmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ShyamKishore Shrivastava, MD</last_name>
      <phone>+912224177163</phone>
      <email>shrivastavask@tmc.gov.in</email>
    </contact_backup>
    <investigator>
      <last_name>Reena Engineer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>May 4, 2010</last_update_submitted>
  <last_update_submitted_qc>May 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Reena Engineer</name_title>
    <organization>Tata Memorial Centre</organization>
  </responsible_party>
  <keyword>recurrent carcinoma cervix</keyword>
  <keyword>Vault carcinoma</keyword>
  <keyword>Tomotherapy</keyword>
  <keyword>Brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

